Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 10;9(9):80. doi: 10.1038/s41389-020-00264-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — a Tumor growth curve for TC32-bearing xenografts (n = 3) treated with 50 mg/kg OT-82 over an initial 4 week treatment period (mice treated days 1–3, 8–10, 15–17, and 22–24), a 2-week treatment interruption, and an additional 4 week treatment period (mice treated days 38–40, 45–47, 52–54, and 59–60). Black arrows represent treatment schedule. b Kaplan–Meier curves representing survival to endpoint (17 mm in longest tumor diameter) for mice (n = 12/group) bearing EWS xenograft tumors (TC32 and PDX) and treated with vehicle or the indicated doses of OT-82, irinotecan (daily on 2 of every 7 days for TC32; 5 of every 7 days for PDX) or the combination. Black arrows represent treatment schedule; red arrows represent final day of treatment. In TC32 xenografts, p = 0.0004 for irinotecan compared to combination, p < 0.0001 for OT-82 compared to combination; in the PDX, p = 0.0018 for irinotecan compared to combination, p = 0.0065 for OT-82 compared to combination using Mantel–Cox analysis. c Kaplan–Meier curves representing survival to endpoint (17 mm in longest tumor diameter) for mice (n = 12/group) bearing EWS xenograft tumors (TC32 and PDX) and treated with vehicle, or the indicated doses of OT-82, niraparib (daily on 5 of every 7 days) or the combination. Black arrows represent treatment schedule; red arrows represent final day of treatment. In TC32 xenografts, p = 0.0001 for niraparib compared to combination, p < 0.0001 for OT-82 compared to combination; in the PDX, p < 0.0001 for niraparib compared to combination, p = 0.0003 for OT-82 compared to combination using Mantel–Cox analysis.